The FDA has accepted for filing the supplemental New Drug Application (sNDA) for pimavanserin (Nuplazid®; Acadia) for the treatment of hallucinations and delusions associated with dementia-related psychosis.
The researchers concluded that risk for MCI was associated with neurodegeneration and neuropsychiatric symptoms among adults aged 50 years and older, and that an abnormal FDG-PET was a stronger driving force for cognitive decline.
The majority of older adults in the sample did not report any depression, anxiety, or stress symptoms, and almost no respondents indicated severe or extremely severe symptoms.
Patients with psychiatric disorders are another population that may be more exposed to COVID-19, and the secondary effects of the pandemic may detract from ongoing treatment, thus worsening overall mental health.
